Special Issue "Novel Strategies to Mitigate Cancer Therapy Side Effects"
Deadline for manuscript submissions: closed (22 November 2022) | Viewed by 19446
Interests: clinical pharmacology; transporter; oncology; chemotherapy-induced toxicity; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals
Although the effectiveness of cancer therapy has improved dramatically in the last few decades, side effects associated with small-molecule cancer drugs remain a tremendous health problem worldwide, as they negatively impact treatment outcome and diminish overall quality of life. The improved understanding of the molecular and/or cellular mechanisms that underlies the development of cancer therapy-induced side effects has resulted in continuing efforts to predict, prevent, and/or treat potentially debilitating adverse events.
In this Special Issue, we invite experts from the field to highlight novel strategies to mitigate cancer therapy-induced side effects, including both predictive and preventative interventions (including those involving genotyping, biomarker phenotyping, population PK, targeted drug treatment), as well as innovative treatment approaches (including symptom management and mechanism-based reversal of injury).
Dr. Shuiying Hu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- side effects
- small-molecule cancer drugs